These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23234557)

  • 1. Gene therapy briefs.
    Philippidis A
    Hum Gene Ther; 2012 Dec; 23(12):1221-3. PubMed ID: 23234557
    [No Abstract]   [Full Text] [Related]  

  • 2. For patients who inherit homozygous familial hypercholesterolemia, 2 new treatments available.
    Morrow T
    Manag Care; 2013 Mar; 22(3):47-8. PubMed ID: 23610808
    [No Abstract]   [Full Text] [Related]  

  • 3. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 4. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid-lowering treatment for homozygous familial hypercholesterolaemia.
    Santos RD
    Lancet; 2013 Apr; 381(9873):1182. PubMed ID: 23561997
    [No Abstract]   [Full Text] [Related]  

  • 6. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
    Smith RJ; Hiatt WR
    JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296
    [No Abstract]   [Full Text] [Related]  

  • 7. Familial hypercholesterolaemia: new treatment options.
    Ezzahti M; Sijbrands EJ; Mulder MT; Roeters van Lennep JE
    Neth J Med; 2013 Jun; 71(5):227-33. PubMed ID: 23799308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial watch: Antisense agent reduces LDL-cholesterol levels in high-risk patients.
    Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043021
    [No Abstract]   [Full Text] [Related]  

  • 10. A lupus drug and FDA approval.
    Merrill JT; Raymond S
    Science; 2005 Apr; 308(5721):497; author reply 497. PubMed ID: 15845832
    [No Abstract]   [Full Text] [Related]  

  • 11. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
    Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
    Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers.
    Messerli FH
    Am Heart J; 2003 Oct; 146(4):568-9. PubMed ID: 14564307
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety signal dampens reception for mipomersen antisense.
    Kling J
    Nat Biotechnol; 2010 Apr; 28(4):295-7. PubMed ID: 20379153
    [No Abstract]   [Full Text] [Related]  

  • 14. Stocks' study renews concerns over insider trading on oncology drugs.
    Goozner M
    J Natl Cancer Inst; 2011 Nov; 103(22):1652-5. PubMed ID: 22025626
    [No Abstract]   [Full Text] [Related]  

  • 15. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug development. Lupus drug company asks FDA for second chance.
    Couzin J
    Science; 2005 Feb; 307(5711):835. PubMed ID: 15705822
    [No Abstract]   [Full Text] [Related]  

  • 17. Torcetrapib and atorvastatin--should marketing drive the research agenda?
    Avorn J
    N Engl J Med; 2005 Jun; 352(25):2573-6. PubMed ID: 15972861
    [No Abstract]   [Full Text] [Related]  

  • 18. The development of novel anti-hyperlipidemic drugs: a tough business gets tougher.
    Krause BR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):945-9. PubMed ID: 18729000
    [No Abstract]   [Full Text] [Related]  

  • 19. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 20. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.